Alzheimer's disease (AD) is the most common cause of dementia worldwide, and its
prevalence is rapidly increasing due to extended lifespans. Among the increasing number of …

Dysregulation of lipid metabolism has emerged as a central component of many
neurodegenerative diseases. Variants of the lipid transport protein, apolipoprotein E …

The biological processes that are disrupted in the Alzheimer's disease (AD) brain remain
incompletely understood. In this study, we analyzed the proteomes of more than 1,000 brain …

Proteomic studies of human Alzheimer's disease brain tissue have potential to identify
protein changes that drive disease, and to identify new drug targets. Here, we analyse 38 …

Amyloid plaques contain many proteins in addition to beta amyloid (Aβ). Previous studies
examining plaque-associated proteins have shown these additional proteins are important; …

Alzheimer's disease (AD) lacks protein biomarkers reflective of its diverse underlying
pathophysiology, hindering diagnostic and therapeutic advancements. Here, we used …

Alzheimer's disease (AD) is characterized by non-linear, genetic-driven pathophysiological
dynamics with high heterogeneity in biological alterations and disease spatial-temporal …

The E4 allele of Apolipoprotein E (APOE) is associated with both metabolic dysfunction and
a heightened pro-inflammatory response: two findings that may be intrinsically linked …

One of the primary genetic risk factors for Alzheimer's disease (AD) is the presence of the Ɛ4
allele of apolipoprotein E (APOE). APOE is a polymorphic lipoprotein that is a major …

The repeated failures of amyloid-targeting therapies have challenged our narrow
understanding of Alzheimer's disease (AD) pathogenesis and inspired wide-ranging …